相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study
Qing Chang et al.
CLINICAL LUNG CANCER (2021)
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
Waisse Waissi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Aubrey L. Miller et al.
CANCERS (2021)
A Novel Nomogram Based on Hepatic and Coagulation Function for Evaluating Outcomes of Intrahepatic Cholangiocarcinoma After Curative Hepatectomy: A Multi-Center Study of 653 Patients
Yunshi Cai et al.
FRONTIERS IN ONCOLOGY (2021)
Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
Hao Qian et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Fei Song et al.
CELL DEATH & DISEASE (2020)
Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis
Chao Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment
Xiao-Hong Xie et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Antitumor effects of anlotinib in thyroid cancer
Xianhui Ruan et al.
ENDOCRINE-RELATED CANCER (2019)
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma
Gangyang Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Ming Zhou et al.
CANCER COMMUNICATIONS (2019)
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
Lili Wang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway
Chao He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Emerging molecular therapeutic targets for cholangiocarcinoma
Sumera Rizvi et al.
JOURNAL OF HEPATOLOGY (2017)
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma
Alessandro Vitale et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells
Carolina Torres et al.
PANCREAS (2016)
Imaging of Cholangiocarcinoma
Susann-Cathrin Olthof et al.
VISCERAL MEDICINE (2016)
Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?
Gaya Spolverato et al.
CANCER (2015)
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
分享论文
